Related Experiment Video
Updated: Jan 4, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.7K
Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
Shayna Sarosiek1, Vaishali Sanchorawala1
1Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Journal of Blood Medicine
|November 8, 2019
Summary
Systemic immunoglobulin light chain (AL) amyloidosis involves misfolded proteins damaging organs. This review details current treatment options for relapsed or refractory AL amyloidosis, guiding multidisciplinary care decisions.
Area of Science:
- Hematology
- Oncology
- Nephrology
Background:
- Systemic immunoglobulin light chain (AL) amyloidosis is caused by misfolded clonal free light chains depositing in organs.
- Plasma cell clones in the bone marrow produce amyloidogenic light chains, driving disease progression.
- While first-line treatments are established, options for relapsed or refractory AL amyloidosis are diverse.
Purpose of the Study:
- To review current treatment options for relapsed or refractory AL amyloidosis.
- To inform treatment decisions in complex patient cases.
Main Methods:
- Literature review of existing treatment modalities.
- Analysis of therapeutic strategies for relapsed/refractory AL amyloidosis.
Main Results:
- Multiple treatment classes are available for relapsed/refractory AL amyloidosis, including immunomodulatory agents, proteasome inhibitors, alkylating agents, and monoclonal antibodies.
- Treatment selection requires careful consideration of patient factors.
Conclusions:
- Multidisciplinary team involvement is crucial for optimizing treatment selection.
- Patient's functional status, disease stage, organ dysfunction, and treatment toxicities must be weighed.
- Current options offer flexibility in managing relapsed or refractory AL amyloidosis.
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:22Alzheimer's Disease: Treatment
722
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
722
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:26Psychosis: Goals of Pharmacotherapy
424
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
424
01:20Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K